 | • レポートコード：MR9773JX4990 • 出版社/出版日：LP Information / 2026年6月 • レポート形態：英語、PDF、130ページ • 納品方法：Eメール（納期：3日） • 産業分類：バイオ |
| Single User（1名様閲覧用） | ￥570,960 (USD3,660) | ▷ お問い合わせ |
| Multi User（10名様閲覧用） | ￥856,440 (USD5,490) | ▷ お問い合わせ |
| Corporate User（閲覧人数無制限） | ￥1,141,920 (USD7,320) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 世界の「in vitroヒトモデル」市場規模は、2025年の2億3600万米ドルから2032年には6億5600万米ドルへと拡大すると予測されており、2026年から2032年にかけて年平均成長率（CAGR）15.9％で成長すると見込まれています。 in vitroヒトモデルとは、ヒトの細胞や組織を基盤とし、3D培養、オルガノイド、微小生理学的システム／オルガン・オン・チップ・プラットフォーム、バイオプリンティング、多細胞共培養などを活用して設計された、ヒトに関連性の高いシステムであり、体外で重要な臓器機能や疾患メカニズムを再現することを目的としています。2次元アッセイや動物実験と比較して、ヒト関連性、制御性、再現性を優先しており、遺伝学、免疫環境、生体力学、流体シグナルにわたるモジュール式設計を可能にすることで、有効性スクリーニング、メカニズム研究、および肝臓・腎臓・心臓への影響などの安全性試験を支援します。この製品の平均粗利益率は55％です。 動物の使用を削減し、ヒトに関連性の高い非臨床手法を採用しようとする規制当局や業界の機運が高まっています。立法措置や規制当局の取り組みにより、新アプローチ法（NAMs）への道が開かれつつあり、一方で適格性評価やパイロット試験の仕組みによって、オルガノイドやオルガン・オン・チップ・システムが規制当局との関わりの中でより重要な位置づけとなりつつあります。これにより、製薬企業のチームは、これらのモデルを探索的な利用から、意思決定を可能にするツールへと移行させるよう促されています。同時に、複雑な疾患、免疫介在性効果、および従来モデルのトランスレーショナルな限界により、ヒトの微小環境をより的確に再現し、開発の早期段階で不確実性を低減できるin vitroヒトシステムへの需要が高まっている。 最大のボトルネックは、高度なモデルを構築することではなく、それらの安定性、比較可能性、および検証可能性を確保することにある。ドナー間のばらつき、ロット間の均一性、エンドポイントの選定、実験室間の再現性、そして目的に適合した統一された品質基準の欠如は、結果の解釈可能性を損なう恐れがある。影響の大きい安全性判断においては、バリデーションの負担、適用範囲の定義、および既存の動物実験・臨床エビデンスチェーンへの統合が決定的な要素となる。品質管理の成熟度が、最終的に研究用プラットフォームが規制対象かつ大規模な調達用途へと移行する速度を左右する。 需要は、単一臓器の測定結果から、多臓器間の相互作用やシステムレベルのリスク評価へと移行しており、現実世界におけるヒトの異質性との関連性も強まっている。開発者は、慢性疾患や代謝に関連する表現型を捉えるため、iPS細胞由来の多様性、免疫・炎症モジュール、動的灌流、および長期培養をますます取り入れている。また、ユースケースは医薬品の研究開発を超えて、食品・化学物質の安全性評価などの分野へと拡大しており、顧客からは、監査可能なデータチェーン、移転可能なSOP、規制当局の要件を満たす文書化に対する期待が高まっている。 上流工程の投入材料は、以下の3つの柱に分類される：ヒト生体材料（初代細胞、iPS細胞株、オルガノイドシードバンク、無血清／定義済み培地、サイトカインおよび成長因子）、 微小環境材料（ECMハイドロゲルおよび合成マトリックス、スキャフォールドおよび表面化学、バイオインク／架橋可能ポリマー）、ならびにエンジニアリング用基板およびセンシングコンポーネント（マイクロ流体チップ材料、膜／コネクター、統合型センサーおよびイメージング読み出し装置）である。この業界では、ばらつきやコンプライアンスリスクを低減するため、動物由来成分を含まない、化学的に定義された、トレーサビリティのある材料システムへの移行が進んでおり、一方で、吸着、透過性、安定したせん断／流動条件といった工学的なパラメータを制御することが、モデルの信頼性を決定づける上流工程における中核的な要素となっています。 「in vitroヒトモデル市場予測」レポートでは、過去の売上高を検証し、2025年の世界のインビトロヒトモデル総売上高を概観するとともに、2026年から2032年までの予測売上高について、地域および市場セクター別の包括的な分析を提供しています。本レポートでは、インビトロ・ヒューマン・モデルの売上高を地域、市場セクター、サブセクター別に分類し、世界のインビトロ・ヒューマン・モデル業界について、百万米ドル単位での詳細な分析を提供しています。 本インサイトレポートは、世界のin vitroヒトモデル市場の全体像を包括的に分析し、製品セグメンテーション、企業設立、収益、市場シェア、最新動向、M&A活動に関連する主要なトレンドを明らかにしています。また、本レポートでは、体外ヒトモデル市場が加速する中、主要グローバル企業の独自の立場をより深く理解するため、体外ヒトモデルのポートフォリオと能力、市場参入戦略、市場での位置づけ、および地理的展開に焦点を当て、各社の戦略を分析しています。 本インサイトレポートでは、体外ヒトモデルの世界的な見通しを形作る主要な市場動向、推進要因、および影響要因を評価し、タイプ別、用途別、地域別、市場規模別に予測を細分化することで、新たに台頭する機会領域を浮き彫りにしています。数百件に及ぶボトムアップ型の定性的・定量的市場データに基づく透明性の高い方法論により、本調査の予測は、世界の体外ヒトモデル市場の現状と将来の軌跡について、極めて精緻な見解を提供します。 本レポートでは、製品タイプ、用途、主要企業、および主要地域・国別に、in vitroヒトモデル市場の包括的な概要、市場シェア、成長機会を提示しています。 タイプ別セグメンテーション： 臓器オンチップシステム 3D組織モデル 幹細胞由来モデル 一次細胞源別セグメンテーション： ヒト一次細胞 iPS細胞由来ヒト細胞 腫瘍細胞株 その他 臓器範囲別セグメンテーション： 単一臓器モデル 多臓器連結モデル その他 用途別セグメンテーション： 創薬 毒性試験 疾患モデリング 本レポートでは、地域別にも市場を分類しています： 南北アメリカ 米国 カナダ メキシコ ブラジル アジア太平洋地域（APAC） 中国 日本 韓国 東南アジア インド オーストラリア ヨーロッパ ドイツ フランス 英国 イタリア ロシア 中東・アフリカ エジプト 南アフリカ イスラエル トルコ GCC諸国 以下に紹介する企業は、主要な専門家からの情報および各社の事業範囲、製品ポートフォリオ、市場浸透度を分析した上で選定されています。 Emulate CN Bio TissUse Mimetas InSphero Thermo Fisher Scientific Merck Corning Lonza Danwang Medical Ketu Medical Accurate International Kuraray N3d Bioscience Reprocell Incorporated 3D Biotek Tara Biosystems Hesperos Draper Laboratory Nortis |
The global In-vitro Human Model market size is predicted to grow from US$ 236 million in 2025 to US$ 656 million in 2032; it is expected to grow at a CAGR of 15.9% from 2026 to 2032.
In-vitro Human Models are engineered, human-relevant systems built on human cells/tissues—leveraging 3D culture, organoids, microphysiological systems/organ-on-chip platforms, bioprinting, and multicellular co-cultures—to recapitulate essential organ functions and disease mechanisms outside the body. Compared with 2D assays and animal studies, they prioritize human relevance, controllability, and reproducibility, enabling modular design across genetics, immune context, biomechanics, and fluidic cues to support efficacy screening, mechanistic studies, and safety testing such as liver/kidney/cardiac liabilities.The average gross profit margin of this product is 55%.
Regulatory and industry momentum toward reducing animal use and adopting human-relevant nonclinical methods is accelerating. Legislative and agency actions are opening pathways for New Approach Methodologies (NAMs), while qualification/pilot mechanisms are bringing organoids and organ-on-chip systems into a more regulator-facing context—encouraging pharma teams to move these models from exploratory use toward decision-enabling tools. At the same time, complex diseases, immune-mediated effects, and the translational limits of conventional models amplify demand for in-vitro human systems that better capture human microenvironments and reduce uncertainty earlier in development.
The key bottleneck is not building sophisticated models, but ensuring they are stable, comparable, and reviewable. Donor variability, batch-to-batch consistency, endpoint selection, cross-lab reproducibility, and the lack of harmonized fit-for-purpose quality standards can undermine interpretability. For high-impact safety decisions, validation burden, boundary-of-applicability definition, and integration into existing animal/clinical evidence chains become decisive. Quality management maturity ultimately governs how quickly research-grade platforms transition into regulated and scaled procurement use.
Demand is shifting from single-organ readouts to multi-organ interaction and system-level risk assessment, with stronger linkage to real-world human heterogeneity. Developers increasingly incorporate iPSC-derived diversity, immune/inflammation modules, dynamic perfusion, and longer-term culture to capture chronic and metabolism-linked phenotypes. Use cases are also expanding beyond drug R&D into areas such as food/chemical safety evaluation, and customers are raising expectations for auditable data chains, transferable SOPs, and regulator-friendly documentation.
Upstream inputs cluster into three pillars: human biological materials (primary cells, iPSC lines, organoid seed banks, serum-free/defined media, cytokines and growth factors), microenvironment materials (ECM hydrogels and synthetic matrices, scaffolds and surface chemistries, bioinks/crosslinkable polymers), and engineering substrates & sensing components (microfluidic chip materials, membranes/connectors, integrated sensors and imaging readouts). The industry is trending toward animal-free, chemically defined, and traceable material systems to reduce variability and compliance risk, while controlling engineering parameters—adsorption, permeability, and stable shear/flow conditions—has become a core upstream determinant of model credibility.
The “In-vitro Human Model Industry Forecast” looks at past sales and reviews total world In-vitro Human Model sales in 2025, providing a comprehensive analysis by region and market sector of projected In-vitro Human Model sales for 2026 through 2032. With In-vitro Human Model sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world In-vitro Human Model industry.
This Insight Report provides a comprehensive analysis of the global In-vitro Human Model landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on In-vitro Human Model portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global In-vitro Human Model market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for In-vitro Human Model and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global In-vitro Human Model.
This report presents a comprehensive overview, market shares, and growth opportunities of In-vitro Human Model market by product type, application, key players and key regions and countries.
Segmentation by Type:
Organ-on-chip Systems
3D Tissue Models
Stem-cell Derived Models
Segmentation by Primary Cell Source:
Primary Human Cells
iPSC-derived Human Cells
Tumor Cell Lines
Others
Segmentation by Organ Scope:
Single-organ Model
Multi-organ Connected Model
Other
Segmentation by Application:
Drug Discovery
Toxicity Testing
Disease Modeling
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company’s coverage, product portfolio, its market penetration.
Emulate
CN Bio
TissUse
Mimetas
InSphero
Thermo Fisher Scientific
Merck
Corning
Lonza
Danwang Medical
Ketu Medical
Accurate International
Kuraray
N3d Bioscience
Reprocell Incorporated
3D Biotek
Tara Biosystems
Hesperos
Draper Laboratory
Nortis
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global In-vitro Human Model Market Size (2021-2032)
2.1.2 In-vitro Human Model Market Size CAGR by Region (2021 VS 2025 VS 2032)
2.1.3 World Current & Future Analysis for In-vitro Human Model by Country/Region (2021, 2025 & 2032)
2.2 In-vitro Human Model Segment by Type
2.2.1 Organ-on-chip Systems
2.2.2 3D Tissue Models
2.2.3 Stem-cell Derived Models
2.2.4 In-vitro Human Model Market Size by Type
2.2.4.1 In-vitro Human Model Market Size CAGR by Type (2021 VS 2025 VS 2032)
2.2.4.2 Global In-vitro Human Model Market Size Market Share by Type (2021-2026)
2.3 In-vitro Human Model Segment by Primary Cell Source
2.3.1 Primary Human Cells
2.3.2 iPSC-derived Human Cells
2.3.3 Tumor Cell Lines
2.3.4 Others
2.3.5 In-vitro Human Model Market Size by Primary Cell Source
2.3.5.1 In-vitro Human Model Market Size CAGR by Primary Cell Source (2021 VS 2025 VS 2032)
2.3.5.2 Global In-vitro Human Model Market Size Market Share by Primary Cell Source (2021-2026)
2.4 In-vitro Human Model Segment by Organ Scope
2.4.1 Single-organ Model
2.4.2 Multi-organ Connected Model
2.4.3 Other
2.4.4 In-vitro Human Model Market Size by Organ Scope
2.4.4.1 In-vitro Human Model Market Size CAGR by Organ Scope (2021 VS 2025 VS 2032)
2.4.4.2 Global In-vitro Human Model Market Size Market Share by Organ Scope (2021-2026)
2.5 In-vitro Human Model Segment by Application
2.5.1 Drug Discovery
2.5.2 Toxicity Testing
2.5.3 Disease Modeling
2.5.4 In-vitro Human Model Market Size by Application
2.5.4.1 In-vitro Human Model Market Size CAGR by Application (2021 VS 2025 VS 2032)
2.5.4.2 Global In-vitro Human Model Market Size Market Share by Application (2021-2026)
3 In-vitro Human Model Market Size by Player
3.1 In-vitro Human Model Market Size Market Share by Player
3.1.1 Global In-vitro Human Model Revenue by Player (2021-2026)
3.1.2 Global In-vitro Human Model Revenue Market Share by Player (2021-2026)
3.2 Global In-vitro Human Model Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 In-vitro Human Model by Region
4.1 In-vitro Human Model Market Size by Region (2021-2026)
4.2 Global In-vitro Human Model Annual Revenue by Country/Region (2021-2026)
4.3 Americas In-vitro Human Model Market Size Growth (2021-2026)
4.4 APAC In-vitro Human Model Market Size Growth (2021-2026)
4.5 Europe In-vitro Human Model Market Size Growth (2021-2026)
4.6 Middle East & Africa In-vitro Human Model Market Size Growth (2021-2026)
5 Americas
5.1 Americas In-vitro Human Model Market Size by Country (2021-2026)
5.2 Americas In-vitro Human Model Market Size by Type (2021-2026)
5.3 Americas In-vitro Human Model Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC In-vitro Human Model Market Size by Region (2021-2026)
6.2 APAC In-vitro Human Model Market Size by Type (2021-2026)
6.3 APAC In-vitro Human Model Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe In-vitro Human Model Market Size by Country (2021-2026)
7.2 Europe In-vitro Human Model Market Size by Type (2021-2026)
7.3 Europe In-vitro Human Model Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa In-vitro Human Model by Region (2021-2026)
8.2 Middle East & Africa In-vitro Human Model Market Size by Type (2021-2026)
8.3 Middle East & Africa In-vitro Human Model Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global In-vitro Human Model Market Forecast
10.1 Global In-vitro Human Model Forecast by Region (2027-2032)
10.1.1 Global In-vitro Human Model Forecast by Region (2027-2032)
10.1.2 Americas In-vitro Human Model Forecast
10.1.3 APAC In-vitro Human Model Forecast
10.1.4 Europe In-vitro Human Model Forecast
10.1.5 Middle East & Africa In-vitro Human Model Forecast
10.2 Americas In-vitro Human Model Forecast by Country (2027-2032)
10.2.1 United States Market In-vitro Human Model Forecast
10.2.2 Canada Market In-vitro Human Model Forecast
10.2.3 Mexico Market In-vitro Human Model Forecast
10.2.4 Brazil Market In-vitro Human Model Forecast
10.3 APAC In-vitro Human Model Forecast by Region (2027-2032)
10.3.1 China In-vitro Human Model Market Forecast
10.3.2 Japan Market In-vitro Human Model Forecast
10.3.3 Korea Market In-vitro Human Model Forecast
10.3.4 Southeast Asia Market In-vitro Human Model Forecast
10.3.5 India Market In-vitro Human Model Forecast
10.3.6 Australia Market In-vitro Human Model Forecast
10.4 Europe In-vitro Human Model Forecast by Country (2027-2032)
10.4.1 Germany Market In-vitro Human Model Forecast
10.4.2 France Market In-vitro Human Model Forecast
10.4.3 UK Market In-vitro Human Model Forecast
10.4.4 Italy Market In-vitro Human Model Forecast
10.4.5 Russia Market In-vitro Human Model Forecast
10.5 Middle East & Africa In-vitro Human Model Forecast by Region (2027-2032)
10.5.1 Egypt Market In-vitro Human Model Forecast
10.5.2 South Africa Market In-vitro Human Model Forecast
10.5.3 Israel Market In-vitro Human Model Forecast
10.5.4 Turkey Market In-vitro Human Model Forecast
10.6 Global In-vitro Human Model Forecast by Type (2027-2032)
10.7 Global In-vitro Human Model Forecast by Application (2027-2032)
10.7.1 GCC Countries Market In-vitro Human Model Forecast
11 Key Players Analysis
11.1 Emulate
11.1.1 Emulate Company Information
11.1.2 Emulate In-vitro Human Model Product Offered
11.1.3 Emulate In-vitro Human Model Revenue, Gross Margin and Market Share (2021-2026)
11.1.4 Emulate Main Business Overview
11.1.5 Emulate Latest Developments
11.2 CN Bio
11.2.1 CN Bio Company Information
11.2.2 CN Bio In-vitro Human Model Product Offered
11.2.3 CN Bio In-vitro Human Model Revenue, Gross Margin and Market Share (2021-2026)
11.2.4 CN Bio Main Business Overview
11.2.5 CN Bio Latest Developments
11.3 TissUse
11.3.1 TissUse Company Information
11.3.2 TissUse In-vitro Human Model Product Offered
11.3.3 TissUse In-vitro Human Model Revenue, Gross Margin and Market Share (2021-2026)
11.3.4 TissUse Main Business Overview
11.3.5 TissUse Latest Developments
11.4 Mimetas
11.4.1 Mimetas Company Information
11.4.2 Mimetas In-vitro Human Model Product Offered
11.4.3 Mimetas In-vitro Human Model Revenue, Gross Margin and Market Share (2021-2026)
11.4.4 Mimetas Main Business Overview
11.4.5 Mimetas Latest Developments
11.5 InSphero
11.5.1 InSphero Company Information
11.5.2 InSphero In-vitro Human Model Product Offered
11.5.3 InSphero In-vitro Human Model Revenue, Gross Margin and Market Share (2021-2026)
11.5.4 InSphero Main Business Overview
11.5.5 InSphero Latest Developments
11.6 Thermo Fisher Scientific
11.6.1 Thermo Fisher Scientific Company Information
11.6.2 Thermo Fisher Scientific In-vitro Human Model Product Offered
11.6.3 Thermo Fisher Scientific In-vitro Human Model Revenue, Gross Margin and Market Share (2021-2026)
11.6.4 Thermo Fisher Scientific Main Business Overview
11.6.5 Thermo Fisher Scientific Latest Developments
11.7 Merck
11.7.1 Merck Company Information
11.7.2 Merck In-vitro Human Model Product Offered
11.7.3 Merck In-vitro Human Model Revenue, Gross Margin and Market Share (2021-2026)
11.7.4 Merck Main Business Overview
11.7.5 Merck Latest Developments
11.8 Corning
11.8.1 Corning Company Information
11.8.2 Corning In-vitro Human Model Product Offered
11.8.3 Corning In-vitro Human Model Revenue, Gross Margin and Market Share (2021-2026)
11.8.4 Corning Main Business Overview
11.8.5 Corning Latest Developments
11.9 Lonza
11.9.1 Lonza Company Information
11.9.2 Lonza In-vitro Human Model Product Offered
11.9.3 Lonza In-vitro Human Model Revenue, Gross Margin and Market Share (2021-2026)
11.9.4 Lonza Main Business Overview
11.9.5 Lonza Latest Developments
11.10 Danwang Medical
11.10.1 Danwang Medical Company Information
11.10.2 Danwang Medical In-vitro Human Model Product Offered
11.10.3 Danwang Medical In-vitro Human Model Revenue, Gross Margin and Market Share (2021-2026)
11.10.4 Danwang Medical Main Business Overview
11.10.5 Danwang Medical Latest Developments
11.11 Ketu Medical
11.11.1 Ketu Medical Company Information
11.11.2 Ketu Medical In-vitro Human Model Product Offered
11.11.3 Ketu Medical In-vitro Human Model Revenue, Gross Margin and Market Share (2021-2026)
11.11.4 Ketu Medical Main Business Overview
11.11.5 Ketu Medical Latest Developments
11.12 Accurate International
11.12.1 Accurate International Company Information
11.12.2 Accurate International In-vitro Human Model Product Offered
11.12.3 Accurate International In-vitro Human Model Revenue, Gross Margin and Market Share (2021-2026)
11.12.4 Accurate International Main Business Overview
11.12.5 Accurate International Latest Developments
11.13 Kuraray
11.13.1 Kuraray Company Information
11.13.2 Kuraray In-vitro Human Model Product Offered
11.13.3 Kuraray In-vitro Human Model Revenue, Gross Margin and Market Share (2021-2026)
11.13.4 Kuraray Main Business Overview
11.13.5 Kuraray Latest Developments
11.14 N3d Bioscience
11.14.1 N3d Bioscience Company Information
11.14.2 N3d Bioscience In-vitro Human Model Product Offered
11.14.3 N3d Bioscience In-vitro Human Model Revenue, Gross Margin and Market Share (2021-2026)
11.14.4 N3d Bioscience Main Business Overview
11.14.5 N3d Bioscience Latest Developments
11.15 Reprocell Incorporated
11.15.1 Reprocell Incorporated Company Information
11.15.2 Reprocell Incorporated In-vitro Human Model Product Offered
11.15.3 Reprocell Incorporated In-vitro Human Model Revenue, Gross Margin and Market Share (2021-2026)
11.15.4 Reprocell Incorporated Main Business Overview
11.15.5 Reprocell Incorporated Latest Developments
11.16 3D Biotek
11.16.1 3D Biotek Company Information
11.16.2 3D Biotek In-vitro Human Model Product Offered
11.16.3 3D Biotek In-vitro Human Model Revenue, Gross Margin and Market Share (2021-2026)
11.16.4 3D Biotek Main Business Overview
11.16.5 3D Biotek Latest Developments
11.17 Tara Biosystems
11.17.1 Tara Biosystems Company Information
11.17.2 Tara Biosystems In-vitro Human Model Product Offered
11.17.3 Tara Biosystems In-vitro Human Model Revenue, Gross Margin and Market Share (2021-2026)
11.17.4 Tara Biosystems Main Business Overview
11.17.5 Tara Biosystems Latest Developments
11.18 Hesperos
11.18.1 Hesperos Company Information
11.18.2 Hesperos In-vitro Human Model Product Offered
11.18.3 Hesperos In-vitro Human Model Revenue, Gross Margin and Market Share (2021-2026)
11.18.4 Hesperos Main Business Overview
11.18.5 Hesperos Latest Developments
11.19 Draper Laboratory
11.19.1 Draper Laboratory Company Information
11.19.2 Draper Laboratory In-vitro Human Model Product Offered
11.19.3 Draper Laboratory In-vitro Human Model Revenue, Gross Margin and Market Share (2021-2026)
11.19.4 Draper Laboratory Main Business Overview
11.19.5 Draper Laboratory Latest Developments
11.20 Nortis
11.20.1 Nortis Company Information
11.20.2 Nortis In-vitro Human Model Product Offered
11.20.3 Nortis In-vitro Human Model Revenue, Gross Margin and Market Share (2021-2026)
11.20.4 Nortis Main Business Overview
11.20.5 Nortis Latest Developments
12 Research Findings and Conclusion
List of Tables
Table 1. In-vitro Human Model Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. In-vitro Human Model Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Organ-on-chip Systems
Table 4. Major Players of 3D Tissue Models
Table 5. Major Players of Stem-cell Derived Models
Table 6. In-vitro Human Model Market Size CAGR by Type (2021 VS 2025 VS 2032) & ($ millions)
Table 7. Global In-vitro Human Model Market Size by Type (2021-2026) & ($ millions)
Table 8. Global In-vitro Human Model Market Size Market Share by Type (2021-2026)
Table 9. Major Players of Primary Human Cells
Table 10. Major Players of iPSC-derived Human Cells
Table 11. Major Players of Tumor Cell Lines
Table 12. Major Players of Others
Table 13. In-vitro Human Model Market Size CAGR by Primary Cell Source (2021 VS 2025 VS 2032) & ($ millions)
Table 14. Global In-vitro Human Model Market Size by Primary Cell Source (2021-2026) & ($ millions)
Table 15. Global In-vitro Human Model Market Size Market Share by Primary Cell Source (2021-2026)
Table 16. Major Players of Single-organ Model
Table 17. Major Players of Multi-organ Connected Model
Table 18. Major Players of Other
Table 19. In-vitro Human Model Market Size CAGR by Organ Scope (2021 VS 2025 VS 2032) & ($ millions)
Table 20. Global In-vitro Human Model Market Size by Organ Scope (2021-2026) & ($ millions)
Table 21. Global In-vitro Human Model Market Size Market Share by Organ Scope (2021-2026)
Table 22. In-vitro Human Model Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 23. Global In-vitro Human Model Market Size by Application (2021-2026) & ($ millions)
Table 24. Global In-vitro Human Model Market Size Market Share by Application (2021-2026)
Table 25. Global In-vitro Human Model Revenue by Player (2021-2026) & ($ millions)
Table 26. Global In-vitro Human Model Revenue Market Share by Player (2021-2026)
Table 27. In-vitro Human Model Key Players Head office and Products Offered
Table 28. In-vitro Human Model Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 29. New Products and Potential Entrants
Table 30. Mergers & Acquisitions, Expansion
Table 31. Global In-vitro Human Model Market Size by Region (2021-2026) & ($ millions)
Table 32. Global In-vitro Human Model Market Size Market Share by Region (2021-2026)
Table 33. Global In-vitro Human Model Revenue by Country/Region (2021-2026) & ($ millions)
Table 34. Global In-vitro Human Model Revenue Market Share by Country/Region (2021-2026)
Table 35. Americas In-vitro Human Model Market Size by Country (2021-2026) & ($ millions)
Table 36. Americas In-vitro Human Model Market Size Market Share by Country (2021-2026)
Table 37. Americas In-vitro Human Model Market Size by Type (2021-2026) & ($ millions)
Table 38. Americas In-vitro Human Model Market Size Market Share by Type (2021-2026)
Table 39. Americas In-vitro Human Model Market Size by Application (2021-2026) & ($ millions)
Table 40. Americas In-vitro Human Model Market Size Market Share by Application (2021-2026)
Table 41. APAC In-vitro Human Model Market Size by Region (2021-2026) & ($ millions)
Table 42. APAC In-vitro Human Model Market Size Market Share by Region (2021-2026)
Table 43. APAC In-vitro Human Model Market Size by Type (2021-2026) & ($ millions)
Table 44. APAC In-vitro Human Model Market Size by Application (2021-2026) & ($ millions)
Table 45. Europe In-vitro Human Model Market Size by Country (2021-2026) & ($ millions)
Table 46. Europe In-vitro Human Model Market Size Market Share by Country (2021-2026)
Table 47. Europe In-vitro Human Model Market Size by Type (2021-2026) & ($ millions)
Table 48. Europe In-vitro Human Model Market Size by Application (2021-2026) & ($ millions)
Table 49. Middle East & Africa In-vitro Human Model Market Size by Region (2021-2026) & ($ millions)
Table 50. Middle East & Africa In-vitro Human Model Market Size by Type (2021-2026) & ($ millions)
Table 51. Middle East & Africa In-vitro Human Model Market Size by Application (2021-2026) & ($ millions)
Table 52. Key Market Drivers & Growth Opportunities of In-vitro Human Model
Table 53. Key Market Challenges & Risks of In-vitro Human Model
Table 54. Key Industry Trends of In-vitro Human Model
Table 55. Global In-vitro Human Model Market Size Forecast by Region (2027-2032) & ($ millions)
Table 56. Global In-vitro Human Model Market Size Market Share Forecast by Region (2027-2032)
Table 57. Global In-vitro Human Model Market Size Forecast by Type (2027-2032) & ($ millions)
Table 58. Global In-vitro Human Model Market Size Forecast by Application (2027-2032) & ($ millions)
Table 59. Emulate Details, Company Type, In-vitro Human Model Area Served and Its Competitors
Table 60. Emulate In-vitro Human Model Product Offered
Table 61. Emulate In-vitro Human Model Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 62. Emulate Main Business
Table 63. Emulate Latest Developments
Table 64. CN Bio Details, Company Type, In-vitro Human Model Area Served and Its Competitors
Table 65. CN Bio In-vitro Human Model Product Offered
Table 66. CN Bio In-vitro Human Model Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 67. CN Bio Main Business
Table 68. CN Bio Latest Developments
Table 69. TissUse Details, Company Type, In-vitro Human Model Area Served and Its Competitors
Table 70. TissUse In-vitro Human Model Product Offered
Table 71. TissUse In-vitro Human Model Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 72. TissUse Main Business
Table 73. TissUse Latest Developments
Table 74. Mimetas Details, Company Type, In-vitro Human Model Area Served and Its Competitors
Table 75. Mimetas In-vitro Human Model Product Offered
Table 76. Mimetas In-vitro Human Model Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 77. Mimetas Main Business
Table 78. Mimetas Latest Developments
Table 79. InSphero Details, Company Type, In-vitro Human Model Area Served and Its Competitors
Table 80. InSphero In-vitro Human Model Product Offered
Table 81. InSphero In-vitro Human Model Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 82. InSphero Main Business
Table 83. InSphero Latest Developments
Table 84. Thermo Fisher Scientific Details, Company Type, In-vitro Human Model Area Served and Its Competitors
Table 85. Thermo Fisher Scientific In-vitro Human Model Product Offered
Table 86. Thermo Fisher Scientific In-vitro Human Model Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 87. Thermo Fisher Scientific Main Business
Table 88. Thermo Fisher Scientific Latest Developments
Table 89. Merck Details, Company Type, In-vitro Human Model Area Served and Its Competitors
Table 90. Merck In-vitro Human Model Product Offered
Table 91. Merck In-vitro Human Model Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 92. Merck Main Business
Table 93. Merck Latest Developments
Table 94. Corning Details, Company Type, In-vitro Human Model Area Served and Its Competitors
Table 95. Corning In-vitro Human Model Product Offered
Table 96. Corning In-vitro Human Model Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 97. Corning Main Business
Table 98. Corning Latest Developments
Table 99. Lonza Details, Company Type, In-vitro Human Model Area Served and Its Competitors
Table 100. Lonza In-vitro Human Model Product Offered
Table 101. Lonza In-vitro Human Model Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 102. Lonza Main Business
Table 103. Lonza Latest Developments
Table 104. Danwang Medical Details, Company Type, In-vitro Human Model Area Served and Its Competitors
Table 105. Danwang Medical In-vitro Human Model Product Offered
Table 106. Danwang Medical In-vitro Human Model Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 107. Danwang Medical Main Business
Table 108. Danwang Medical Latest Developments
Table 109. Ketu Medical Details, Company Type, In-vitro Human Model Area Served and Its Competitors
Table 110. Ketu Medical In-vitro Human Model Product Offered
Table 111. Ketu Medical In-vitro Human Model Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 112. Ketu Medical Main Business
Table 113. Ketu Medical Latest Developments
Table 114. Accurate International Details, Company Type, In-vitro Human Model Area Served and Its Competitors
Table 115. Accurate International In-vitro Human Model Product Offered
Table 116. Accurate International In-vitro Human Model Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 117. Accurate International Main Business
Table 118. Accurate International Latest Developments
Table 119. Kuraray Details, Company Type, In-vitro Human Model Area Served and Its Competitors
Table 120. Kuraray In-vitro Human Model Product Offered
Table 121. Kuraray In-vitro Human Model Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 122. Kuraray Main Business
Table 123. Kuraray Latest Developments
Table 124. N3d Bioscience Details, Company Type, In-vitro Human Model Area Served and Its Competitors
Table 125. N3d Bioscience In-vitro Human Model Product Offered
Table 126. N3d Bioscience In-vitro Human Model Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 127. N3d Bioscience Main Business
Table 128. N3d Bioscience Latest Developments
Table 129. Reprocell Incorporated Details, Company Type, In-vitro Human Model Area Served and Its Competitors
Table 130. Reprocell Incorporated In-vitro Human Model Product Offered
Table 131. Reprocell Incorporated In-vitro Human Model Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 132. Reprocell Incorporated Main Business
Table 133. Reprocell Incorporated Latest Developments
Table 134. 3D Biotek Details, Company Type, In-vitro Human Model Area Served and Its Competitors
Table 135. 3D Biotek In-vitro Human Model Product Offered
Table 136. 3D Biotek In-vitro Human Model Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 137. 3D Biotek Main Business
Table 138. 3D Biotek Latest Developments
Table 139. Tara Biosystems Details, Company Type, In-vitro Human Model Area Served and Its Competitors
Table 140. Tara Biosystems In-vitro Human Model Product Offered
Table 141. Tara Biosystems In-vitro Human Model Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 142. Tara Biosystems Main Business
Table 143. Tara Biosystems Latest Developments
Table 144. Hesperos Details, Company Type, In-vitro Human Model Area Served and Its Competitors
Table 145. Hesperos In-vitro Human Model Product Offered
Table 146. Hesperos In-vitro Human Model Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 147. Hesperos Main Business
Table 148. Hesperos Latest Developments
Table 149. Draper Laboratory Details, Company Type, In-vitro Human Model Area Served and Its Competitors
Table 150. Draper Laboratory In-vitro Human Model Product Offered
Table 151. Draper Laboratory In-vitro Human Model Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 152. Draper Laboratory Main Business
Table 153. Draper Laboratory Latest Developments
Table 154. Nortis Details, Company Type, In-vitro Human Model Area Served and Its Competitors
Table 155. Nortis In-vitro Human Model Product Offered
Table 156. Nortis In-vitro Human Model Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 157. Nortis Main Business
Table 158. Nortis Latest Developments
eスポーツの日本市場（2026年～2034年） The Japan esports market size was valued at USD 156.8 Million in 2025. Looking forward, IMARC Group estimates the market to reach USD 417.6 Million by 2034, exhibiting a CAGR of 11.20% from 2026-2034. The market is witnessing significant expansion, principally bolstered by growing popularity among y…- 研究用抗体の日本市場（2026年～2034年） Japan research antibodies market size reached USD 255.6 Million in 2025. Looking forward, IMARC Group expects the market to reach USD 510.9 Million by 2034, exhibiting a growth rate (CAGR) of 8.00% during 2026-2034. Continuous medical advancements, coupled with the expanding biotechnology industry, …
- 航空機用ギアボックスの日本市場（～2031年） The Aircraft Gearbox market in Japan has evolved significantly over the decades, reflecting the country’s broader advancements in aerospace engineering, precision manufacturing, and propulsion technology. Initially, during the 1950s and 1960s, Japan’s aircraft gearbox production was limited and larg…
- ペットフード原料の日本市場（～2031年） The Pet Food Ingredient sector in Japan is a highly sophisticated and mature market, characterized by a meticulous approach to pet nutrition and a strong emphasis on quality and safety. This market's fundamental purpose is to supply the specialized components necessary for formulating complete and b…
- 海藻の日本市場（2026年～2034年） Japan seaweed market size reached USD 571.2 Million in 2025. Looking forward, IMARC Group expects the market to reach USD 1,036.1 Million by 2034, exhibiting a growth rate (CAGR) of 6.84% during 2026-2034. The rising consumer inclination towards plant-based diets and alternative protein sources, alo…